Kefzol (Cefazolin)

Cefazolin works by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the wall, causing osmotic lysis of the bacterium. The action is time‑dependent and results in bactericidal activity during bacterial growth.

The dose of Kefzol is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and route of administration. Typical regimens range from a single pre‑operative dose for prophylaxis to multiple daily doses for therapeutic treatment, but exact amounts must be set by a qualified health professional.

Data on cefazolin use in pregnancy and lactation are limited. The drug is classified as Category B in many regions, indicating no evidence of fetal risk in animal studies but insufficient human data. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when safer options are available.

To order Kefzol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Compared with earlier‑generation cephalosporins, cefazolin offers a broader spectrum against many Gram‑positive organisms and improved stability for injection. It is often preferred over penicillins for surgical prophylaxis because of its longer half‑life and lower risk of allergic cross‑reaction. However, it lacks activity against Pseudomonas aeruginosa, which may require a different class of drug.

Kefzol should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product is reconstituted for use, follow the manufacturer’s guidance on stability and discard any unused portion after the recommended time.

Kefzol is supplied as a sterile injectable solution for intramuscular or intravenous administration. The route and rate of injection are selected by the prescriber based on the clinical indication. Intravenous infusion is typically given over 5‑30 minutes, while intramuscular injection is administered into a large muscle group.

The most serious adverse events linked to cefazolin include anaphylactic or severe allergic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, hemolytic anemia, thrombocytopenia, and acute renal failure. Prompt recognition and immediate medical attention are essential if any of these reactions occur.

Kefzol should be avoided in individuals with a known hypersensitivity to cefazolin, other cephalosporins, or penicillins. Patients with a history of severe allergic reactions to beta‑lactam antibiotics should not receive the drug. Caution is also advised for patients with significant renal impairment, as dose adjustments may be required.